Power3 Medical Products launches Phase II trials for Alzheimer's and Parkinson's diseases blood diagnostic tests

BioMedReports.com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a special report on Power3 Medical Products (OTCBB: PWRM), the developer of several blood tests designed for early detection, monitoring and targeting of diseases like Alzheimer's, Parkinson's and breast cancer.

With 10 years of development of their technology and intellectual property, and with commercialization in sight, Power3 is at a critical point in the company's growth. Company CEO, Helen Park told BioMedReports on Tuesday afternoon:

"Power3 Medical Products has recently completed the Phase I Clinical Trials for Alzheimer's and Parkinson's diseases blood diagnostic tests with better than expected results and launched the Phase II clinical trials for both of these diseases. Our Chief Scientific Officer, Dr. Ira Goldknopf, is reporting new information on these results at the BIT meeting in China this week."

The medical community's interest in these new tests, huge market potential, pending positive news, partnerships and technical analysis here look very solid and the stock will open on Wednesday roughly three cents away from potential break-out over a previous level of resistance and previous high.

The complete report is available now at BioMedReports.com:

http://biomedreports.com/component/content/article/56-top-leading-news/18487-ready-to-run-power3-medical-products-otcpwrm.html